Abstract
Distinguishing primary aldosteronism from secondary hyperaldosteronism is traditionally based on reciprocal changes in plasma renin and aldosterone within the renin-angiotensin-aldosterone system (RAAS). We report a rare “mixed” hyperaldosteronism phenotype in a 41-year-old woman with a 14-year history of refractory hypertension and hypokalemia. Biochemical testing demonstrated extreme plasma renin elevation (1,872.00 μIU/mL) and high aldosterone (81.1 ng/dL), which initially suggested secondary hyperaldosteronism, but imaging identified the coexistence of a right renal mass and a right endocrine-active adrenal nodule. Following laparoscopic resection of both lesions, histopathology confirmed an atypical juxtaglomerular cell tumor (reninoma) with uncertain malignant potential (Ki-67 index 8%-10%) and an aldosterone-producing nodule (APN). Postoperatively, plasma renin normalized and refractory hypertension resolved without antihypertensive medication. The aldosterone secretion is considered to originate from both the autonomous APN that bypasses normal RAAS regulation and responsive non-neoplastic (zona glomerulosa) cells stimulated by chronic RAAS activation from the reninoma. This rare case of coexisting atypical reninoma and APN highlights the limitations of relying solely on renin-aldosterone patterns and emphasizes that comprehensive multimodal imaging and endocrine evaluation are necessary to resolve diagnostic paradoxes in complex secondary hypertension.
Index Words: Primary aldosteronism, secondary hyperaldosteronism, reninoma, aldosterone-producing nodule, mixed hyperaldosteronism
Introduction
Clinically, measurement of plasma renin and aldosterone levels is fundamental to the differential diagnosis of primary aldosteronism (PA) and secondary hyperaldosteronism (SH).1,2 In PA, autonomous aldosterone secretion—most commonly from an aldosterone-producing diffuse hyperplasia or an aldosterone-producing adenoma—leads to aldosterone excess with suppressed renin via negative feedback within the renin-angiotensin-aldosterone system (RAAS), which causes high aldosterone levels and low renin.3,4 Conversely, SH is characterized by concomitant elevation of both renin and aldosterone, typically driven by factors that activate juxtaglomerular cells, such as renal hypoperfusion or parenchymal diseases. In rare cases, renin-secreting tumors can independently lead to excessive renin production.5 This RAAS-based framework underpins both diagnostic and therapeutic strategies for PA and SH.6
A reninoma, or juxtaglomerular cell tumor, is a rare renal neoplasm that autonomously secretes renin, representing a curable cause of SH.7, 8, 9 Surgical resection usually results in rapid biochemical normalization and clinical resolution.
This report describes an unusual and diagnostically challenging case involving the coexistence of an atypical reninoma and aldosterone-producing nodule (APN).10 This dual pathology generated a paradoxical endocrine profile that challenged the conventional dichotomous model used to distinguish PA from SH.
This case highlights key diagnostic pitfalls associated with a “mixed” hyperaldosteronism state in which biochemical markers and imaging morphological findings are contradictory. Through comprehensive biochemical, radiological, and pathological assessment, we explored the pathophysiological state between chronic RAAS overactivation and the development or activation of aldosterone-producing adrenal nodules.
Case Report
This case report was written in compliance with the CAse REport (CARE) guidelines. Written informed consent was obtained from the patient for publication.
A 41-year-old woman with a 14-year history of hypertension (onset during pregnancy) was admitted for evaluation of poorly controlled blood pressure (maximum 190/90 mm Hg). Her antihypertensive treatment regimen included metoprolol, nifedipine, and telmisartan. On admission, her blood pressure was 164/89 mm Hg and heart rate was 86 beats/min, and laboratory evaluation revealed persistent hypokalemia (3.3-3.5 mmol/L; reference: 3.5-5.1 mmol/L).
Following a 2-week washout of antihypertensive medications to allow accurate RAAS assessment, biochemical testing demonstrated a markedly elevated plasma renin concentration (1,872.00 μIU/mL; reference: 4.4-46.1 μIU/mL) and a significantly increased plasma aldosterone level (81.1 ng/dL; reference: 3.0-35.3 ng/dL). The resulting aldosterone-to-renin ratio was 0.04 (reference: <3.7). This pattern initially suggested renin-mediated SH. Otherwise, biochemical markers were negative.
Contrast-enhanced computed tomography angiography excluded renal artery stenosis, the potential cause of SH, but identified the following 2 discrete lesions: a 1.8-cm right renal cortical mass and a 1.1-cm right adrenal nodule (Fig 1A, B). Subsequent magnetic resonance imaging characterized the renal lesion as isointense on T1-weighted imaging and heterogeneous on T2-weighted imaging, findings consistent with a reninoma as reported (Fig 1C, D). 18F-Pentixafor positron emission tomography–computed tomography demonstrated increased metabolic uptake within the adrenal lesion, providing functional evidence of endocrine activity (Fig 1E).
Figure 1.

Radiological and pathological features of coexisting reninoma and APN. (A) Contrast-enhanced computed tomography image revealing a right renal cortical mass (long arrows) in the hilum with indistinct margins and mild heterogeneous enhancement and (B) a well-defined right adrenal nodule (long arrow) in the lateral limb, suggestive of an adrenal cortical adenoma. (C) Magnetic resonance image revealing the renal lesion (long arrow) is isointense on T1-weighted imaging and (D) heterogeneous on T2-weighted imaging, findings consistent with a reninoma. (E) 18F-Pentixafor PET-CT image showing increased metabolic uptake in the adrenal lesion (short arrows; SUV max = 3.7), indicating endocrine activity. (F) Gross resected specimens showing the renal tumor (upper) and the adrenal adenoma (lower) (scale bar, 5 mm). (G) Renal histopathology image (hematoxylin and eosin stain; original magnification, ×200) demonstrating a relatively distinct demarcation from the adjacent renal parenchyma, and neoplastic cells are tightly packed in sheet-like patterns, with partial perivascular distribution, consistent with reninoma (scale bar, 50 μm). (H) Renal immunohistochemistry image (CD34 stain; original magnification, ×400) revealing diffuse perivascular and delicate vascular network expression of CD34 (brown) within the tumor, confirming the prominent vascular architecture characteristic of reninoma (scale bar, 25 μm). (I) Renal immunohistochemistry image (vimentin stain; original magnification, ×400) revealing strong, diffuse cytoplasmic expression of vimentin (brown) in the neoplastic cells, supporting the mesenchymal differentiation profile typically observed in reninoma (scale bar, 25 μm). (J) Adrenal immunohistochemistry image (CYP11B2 stain; original magnification, ×200) revealing strong, diffuse cytoplasmic expression of CYP11B2 (brown) in the neoplastic cells, which are arranged in nested to trabecular patterns, confirming the functional status of the APN (scale bar, 50 μm). (K) Transmission electron microscopy image demonstrating characteristic highly electron-dense secretory granules in the cytoplasm of tumor cells (thin arrows; scale bar, 500 nm). (L) Adrenal histopathology image (hematoxylin and eosin stain; original magnification, ×200) revealing uniform adrenal cortical cells with round to oval nuclei, finely stippled chromatin, inconspicuous nucleoli, and abundant eosinophilic to vacuolated cytoplasm, consistent with an APN (scale bar, 50 μm). Abbreviations: APN, aldosterone-producing nodule; PET-CT, positron emission tomography--computed tomography; SUV, standardized uptake value.
Evaluation for hypertension-mediated organ damage revealed impaired left ventricular diastolic function on echocardiography. Renal assessment showed no proteinuria, but low serum creatinine (37 μmol/L; reference: 41-73 μmol/L) and an elevated estimated glomerular filtration rate (178 mL/min/1.73 m2; reference: 80-120 mL/min/1.73 m2) indicated glomerular hyperfiltration. No visual disturbances or clinical signs of malignant hypertension were present. In addition, cranial computed tomography angiography identified noncalcified plaques causing moderate stenosis in the bilateral posterior cerebral arteries.
The patient underwent laparoscopic right renal tumor enucleation combined with laparoscopic right adrenalectomy for lesion resection (Fig 1F). Postoperatively, both plasma renin (4.3 μIU/mL; reference range: 4.4-46.1 μIU/mL) and aldosterone (17.9 ng/dL; reference range: 3.0-35.3 ng/dL) levels rapidly normalized. Within 1 month, hypokalemia resolved, and the previous resolution of refractory hypertension achieved clinical remission without antihypertensive medication.
On histopathology, the 1.9-cm renal mass was confirmed as juxtaglomerular cell tumor/reninoma (Fig 1G). Notably, the tumor exhibited atypical features, including focal local invasion, cytologic atypia, occasional mitotic figures, and a Ki-67 proliferation index of 8%-10%, consistent with a reninoma of “uncertain malignant potential.” Immunohistochemical staining showed positive expression of CD34 (Fig 1H) and vimentin (Fig 1I) in the tumor cells, further confirming the diagnosis of reninoma. The tumor showed positive staining for caldesmon (Fig S1A) and calponin (Fig S1B) as well as synaptophysin (Fig S1C), findings that are characteristic of juxtaglomerular cell tumors. Electron microscopy demonstrated characteristic renin-containing secretory granules (Fig 1J). The 0.8-cm adrenal lesion showed strong CYP11B2 (aldosterone synthase) immunoreactivity (Fig 1L), supporting the diagnosis of an APN (Fig 1K).
Discussion
This case presented an atypical hyperaldosteronism phenotype with the concomitant elevation of renin and aldosterone. Unlike classical PA with high aldosterone and suppressed renin, the primary driver in this patient was a reninoma—excessive autonomous secretion of renin from the renal tumor stimulated the adrenal zona glomerulosa, causing severe SH. Concurrently, multimodal imaging (especially increased 18F-Pentixafor uptake) and histopathology (strong CYP11B2 positivity) also confirmed a functional right adrenal APN, which likely contributed secondarily to the overall aldosterone excess.
The diagnostic paradox—in which adrenal morphology suggested PA but renin biochemistry indicated SH—was resolved through the integration of multiple imaging modalities (Fig 2). Although computed tomography angiography was essential for excluding renovascular causes, magnetic resonance imaging helped characterize the renal mass (isointense on T1-weighted imaging; heterogeneous on T2-weighted imaging). Crucially, 18F-Pentixafor positron emission tomography–computed tomography served as the “tie-breaker” by providing evidence of “radioactivity” and biological activities within the adrenal nodule. The positron emission tomography–computed tomography imaging supported an endocrine-active adrenal nodule, which is frequently encountered in SH states.
Figure 2.

Integrated diagnostic workflow of coexisting reninoma and APN. (1) Biochemical Screening: shows markedly elevated plasma renin and aldosterone, and low ARR, supporting secondary hyperaldosteronism (SH; solid arrows), excluding primary aldosteronism (PA; dashed arrows). The aldosterone excess reflects a “mixed” pattern: partially autonomous (from APN) and partially renin driven (from reninoma). (2) Imaging Evaluation: identifies and characterizes dual lesions, whereas CTA excludes renal artery stenosis. (3) Diagnostic Paradox: highlights the clinical conflict in which the patient presents with a functional adrenal nodule on 18F-Pentixafor PET-CT (supporting PA) despite extreme renin elevation (supporting SH) caused by a coexisting reninoma. (4) Resolution and outcomes: laparoscopic dual resection and pathology confirmed an atypical reninoma and an APN. Postoperative renin, blood pressure, and potassium normalized, with long-term surveillance indicated. Abbreviations: APN, aldosterone-producing nodule; CTA, computed tomography; MRI, magnetic resonance imaging; PET-CT, positron emission tomography--computed tomography.
Chronic exposure to elevated angiotensin II, secondary to the reninoma, may have exerted a trophic effect on the adrenal cortex, inducing diffuse or nodular hyperplasia.11,12 This case suggests a pathophysiological state in which the reninoma physiologically stimulated non-neoplastic adrenal tissue to produce aldosterone, whereas the APN simultaneously produced it autonomously.10,13 This distinction is the core of the “mixed” phenotype. This interpretation is supported by normalization of aldosterone levels following resection of both the adrenal nodule and the reninoma.
APN is primarily viewed as a “disease of defective ion channels” and typically harbors somatic mutations in genes such as KCNJ5, CACNA1D, etc.14,15 These mutations drive constitutive membrane depolarization, leading to augmented neoplastic cell proliferation and autonomous CYP11B2 transcription (aldosterone synthase), allowing cells to bypass normal physiological RAAS signaling to produce aldosterone and proliferate.10,14,15 These nodules are thought to arise from precursor lesions termed aldosterone-producing micronodules,10 as these subcentimeter clusters frequently harbor the same ion-channel mutations found in larger tumors.
Although most reninomas demonstrate benign behavior with a low Ki-67 proliferation index (<2%),16 the significantly elevated Ki-67 index (8%-10%) in this case, alongside cytologic atypia and local invasion, suggests increased malignant potential and risk of recurrence.17 The exceptionally high plasma renin concentration (1,872.00 μIU/mL)—more than 40-fold above the upper limit of normal—likely contributed to severe RAAS-mediated target-organ damages,18,19 mandating long-term surveillance.
A limitation of this report is that neither renal vein sampling nor adrenal vein sampling was performed. Nevertheless, the clinical diagnosis was established with sufficient certainty based on the convergence of biochemical, imaging, and histopathological evidence.
In conclusion, this case reports a rare finding of coexisting atypical reninoma and APN, resulting in a mixed hyperaldosteronism that defies conventional diagnostic algorithms. This case highlights the limitations of relying solely on renin-aldosterone patterns and emphasizes that comprehensive multimodal imaging and endocrine evaluation are necessary to resolve diagnostic paradoxes in complex secondary hypertension.
Article Information
Authors’ Full Names and Academic Degrees
Jingna Luo, MD, Xiao Li, MD, Zonghua Wen, MD, Wanjing Liu, MD, Yong Li, MD, Hongyan Pan, MD, Qiang Li, MD, Ang Li, MD, Jicheng Lv, MD, and Qian Li, MD.
Support
This work was supported by the HaiYa Young Scientist Foundation of Shenzhen University General Hospital (grant number: 2025-HY008) and Shenzhen Science and Technology Program (grant number: KJZD20240903095000002).
Financial Disclosure
The authors declare that they have no relevant financial interests.
Acknowledgments
The authors would like to thank the Department of Pathology of Shenzhen University General Hospital for their professional pathological diagnosis and immunohistochemical staining support. The authors also thank Guangzhou Da An Clinical Laboratory Center for providing the electron microscopy technical service. The authors also extend their special thanks to the patient for her consent to participate in this study and for allowing the publication of her clinical and pathological data.
Patient Protections
The authors declare that they have obtained consent from the patient reported in this article for publication of the information about her that appears within this Case Report.
Peer Review
Received March 31, 2026. Evaluated by 1 external peer reviewer, with direct editorial input from the Editor-in-Chief. Accepted in revised form June 10, 2026.
Footnotes
Complete author and article information provided before references.
Figure S1: Immunohistochemical Demonstration of Dual Myogenic-Neuroendocrine Differentiation in Reninoma.
Supplementary Material
Figure S1.
References
- 1.Funder J.W., Carey R.M., Mantero F., et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2016;101(5):1889–1916. doi: 10.1210/jc.2015-4061. [DOI] [PubMed] [Google Scholar]
- 2.O'Shea P.M., Griffin T.P., Denieffe S., Fitzgibbon M.C. The aldosterone to renin ratio in the diagnosis of primary aldosteronism: promises and challenges. Int J Clin Pract. 2019;73(7) doi: 10.1111/ijcp.13353. [DOI] [PubMed] [Google Scholar]
- 3.Reincke M., Bancos I., Mulatero P., Scholl U.I., Stowasser M., Williams T.A. Diagnosis and treatment of primary aldosteronism. Lancet Diabetes Endocrinol. 2021;9(12):876–892. doi: 10.1016/S2213-8587(21)00210-2. [DOI] [PubMed] [Google Scholar]
- 4.Zennaro M.C., Boulkroun S., Fernandes-Rosa F.L. Pathogenesis and treatment of primary aldosteronism. Nat Rev Endocrinol. 2020;16(10):578–589. doi: 10.1038/s41574-020-0382-4. [DOI] [PubMed] [Google Scholar]
- 5.Trnka P., Orellana L., Walsh M., Pool L., Borzi P. Reninoma: an uncommon cause of renin-mediated hypertension. Front Pediatr. 2014;2:89. doi: 10.3389/fped.2014.00089. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Sarathy H., Salman L.A., Lee C., Cohen J.B. Evaluation and management of secondary hypertension. Med Clin North Am. 2022;106(2):269–283. doi: 10.1016/j.mcna.2021.11.004. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Hayes A.G., Stowasser M., Umapathysivam M.M., Falhammar H., Torpy D.J. Approach to the patient: reninoma. J Clin Endocrinol Metab. 2024;109(2):e809–e816. doi: 10.1210/clinem/dgad516. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Wolley M., Gordon R.D., Stowasser M. Reninoma: the importance of renal vein renin ratios for lateralisation and diagnosis. Am J Nephrol. 2014;39(1):16–19. doi: 10.1159/000357410. [DOI] [PubMed] [Google Scholar]
- 9.Xue M., Chen Y., Zhang J., Guan Y., Yang L., Wu B. Reninoma coexisting with adrenal adenoma during pregnancy: a case report. Oncol Lett. 2017;13(5):3186–3190. doi: 10.3892/ol.2017.5802. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Mete O., Erickson L.A., Juhlin C.C., et al. Overview of the 2022 WHO Classification of Adrenal Cortical Tumors. Endocr Pathol. 2022;33(1):155–196. doi: 10.1007/s12022-022-09710-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Pawlikowski M., Gruszka A., Mucha S., Melen-Mucha G. Angiotensins II and IV stimulate the rat adrenocortical cell proliferation acting via different receptors. Endocr Regul. 2001;35(3):139–142. [PubMed] [Google Scholar]
- 12.Otis M., Campbell S., Payet M.D., Gallo-Payet N. The growth-promoting effects of angiotensin II in adrenal glomerulosa cells: an interactive tale. Mol Cell Endocrinol. 2007;273(1-2):1–5. doi: 10.1016/j.mce.2007.05.006. [DOI] [PubMed] [Google Scholar]
- 13.Lymperopoulos A., Borges J.I., Suster M.S. Angiotensin II-dependent aldosterone production in the adrenal cortex. Vitam Horm. 2024;124:393–404. doi: 10.1016/bs.vh.2023.05.001. [DOI] [PubMed] [Google Scholar]
- 14.Williams T.A., Monticone S., Schack V.R., et al. Somatic ATP1A1, ATP2B3, and KCNJ5 mutations in aldosterone-producing adenomas. Hypertension. 2014;63(1):188–195. doi: 10.1161/HYPERTENSIONAHA.113.01733. [DOI] [PubMed] [Google Scholar]
- 15.Azizan E.A., Poulsen H., Tuluc P., et al. Somatic mutations in ATP1A1 and CACNA1D underlie a common subtype of adrenal hypertension. Nat Genet. 2013;45(9):1055–1060. doi: 10.1038/ng.2716. [DOI] [PubMed] [Google Scholar]
- 16.Wang F., Shi C., Cui Y., Li C., Tong A. Juxtaglomerular cell tumor: clinical and immunohistochemical features. J Clin Hypertens (Greenwich) 2017;19(8):807–812. doi: 10.1111/jch.12997. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Duan X., Bruneval P., Hammadeh R., et al. Metastatic juxtaglomerular cell tumor in a 52-year-old man. Am J Surg Pathol. 2004;28(8):1098–1102. doi: 10.1097/01.pas.0000126722.29212.a7. [DOI] [PubMed] [Google Scholar]
- 18.Cesari M., Letizia C., Angeli P., Sciomer S., Rosi S., Rossi G.P. Cardiac remodeling in patients with primary and secondary aldosteronism: a tissue doppler study. Circ Cardiovasc Imaging. 2016;9(6) doi: 10.1161/CIRCIMAGING.116.004815. [DOI] [PubMed] [Google Scholar]
- 19.Miyake A., Endo K., Hayashi K., et al. Role of aldosterone in various target organ damage in patients with hypertensive emergency: a cross-sectional study. BMC Nephrol. 2024;25(1):342. doi: 10.1186/s12882-024-03769-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Figure S1.
